Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.33 |
| ▸ | USP2 | O75604 | 10/20 | 0.33 |
| ▸ | CASP1 | P29466 | 10/20 | 0.33 |
| ▸ | CASP7 | P55210 | 10/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.33 |
| ▸ | MEN1 | O00255 | 7/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.33 |
| ▸ | TSHR | P16473 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 6/20 | 0.33 |
| ▸ | GLA | P06280 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975981 | 0.92 | ALDH1A1 (0.33) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL13685201 | 0.87 | CXCR4 (0.34) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL5149162 | 0.85 | PLA2G7 (0.40) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL2977258 | 0.83 | MEN1 (0.33) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL5147397 | 0.80 | CXCR4 (0.34) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL2980191 | 0.78 | JAK2 (0.33) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL5147316 | 0.77 | PLA2G7 (0.39) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL27708082 | 0.77 | KDM4E (0.33) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2977483 | 0.76 | MEN1 (0.31) | ALDH1A1USP2CASP1CASP7HIF1A | |
| SCHEMBL5147385 | 0.76 | MAPK1 (0.35) | ALDH1A1USP2CASP1CASP7HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | claimed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | claimed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | claimed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | ALDH1A1 1565/4885USP2 3167/4885CASP1 2189/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | ALDH1A1 1565/4885USP2 3167/4885CASP1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.